Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

Favicon for changeflow.com

EP3861011B1: Binders for Inhibiting Multimeric Protein Formation

The European Patent Office has granted patent EP3861011B1 for "Binders for inhibiting formation of multimeric proteins." This patent, effective March 18, 2026, covers specific biotechnological applications related to protein formation.

Routine Rule Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3774875B1: Surfactant Protein D Compositions

The European Patent Office has granted patent EP3774875B1 for "Methods and Compositions Comprising Surfactant Protein D (SP-D)". The patent was granted on March 18, 2026, and covers various applications and compositions related to SP-D.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant: Method for obtaining improved fitness sperm cells

The European Patent Office has granted patent EP3752597B1 for a method to obtain a sperm cell population with improved fitness. The patent is effective March 18, 2026, and covers various designated states within the European Union.

Routine Rule Healthcare
Favicon for changeflow.com

EPO Patent EP3699284B1: U1 Snrnp Regulates Gene Expression

The European Patent Office has granted patent EP3699284B1, titled 'U1 Snrnp Regulates Gene Expression and Modulates Oncogenicity'. This patent relates to specific gene regulation mechanisms and their potential impact on oncogenicity, with implications for biotechnology and pharmaceutical research.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3735459B1: DNA-Based Digital Information Storage

The European Patent Office has granted patent EP3735459B1 for DNA-based digital information storage. The patent, listing Brian Wayne Bramlett and Bill James Peck as inventors, was published on March 18, 2026. This grant pertains to novel methods and systems for utilizing DNA for data storage.

Routine Notice Intellectual Property
Favicon for changeflow.com

EPO Grants Gene Therapy Patent EP3752608B1

The European Patent Office (EPO) has granted patent EP3752608B1 for a gene therapy related to the FAAH pseudogene. The patent was officially granted on March 18, 2026, and covers various European states.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent Grant EP3707250B1: SO3 Chromatography for Virus Purification

The European Patent Office has granted patent EP3707250B1 for a method of virus purification using SO3 chromatography. This patent is designated for use in multiple European states and relates to advancements in biotechnology for pharmaceutical applications.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent EP3612195B1: Stimulating Satellite Stem Cell Division

The European Patent Office has granted patent EP3612195B1 for a method of stimulating asymmetric division of satellite stem cells. This patent, effective March 18, 2026, covers specific applications in biotechnology and regenerative medicine.

Routine Rule Pharmaceuticals
Favicon for changeflow.com

Hydrogel Patent for Cell Culture and Biomedical Applications

The European Patent Office has granted patent EP3609956B1 for a hydrogel intended for cell culture and biomedical applications. The patent lists Hongzhou Huang as the inventor and covers various International Patent Classifications related to biomaterials and cell culture.

Routine Notice Pharmaceuticals
Favicon for changeflow.com

EPO Patent EP3688142B1: Isolating T Cells for P53 Cancer Mutation

The European Patent Office has granted patent EP3688142B1, titled 'Methods of Isolating T Cells Having Antigenic Specificity for a P53 Cancer-Specific Mutation'. This patent relates to methods for isolating T cells for cancer treatment and is designated for multiple European states.

Routine Rule Healthcare

Showing 13721–13730 of 35,748 changes

1 1371 1372 1373 1374 1375 3575

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.